← FDA DRUG APPROVALS

FDA ANDA · ANDA079043

FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI

Sponsor: DR REDDYS LABS LTD

APPLICATION
ANDA079043
TYPE
ANDA
ORIGINAL APPROVAL
2010-03-17
LATEST ACTION
2022-05-17
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Over-the-counter

Products

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDEOver-the-counter
FEXOFENADINE HYDROCHLORIDE 180MG, PSEUDOEPHEDRINE HYDROCHLORIDE 240MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2022-05-17Manufacturing (CMC) · Supplement 6 · unknownAP
2016-01-26Labeling · Supplement 5 · standardAP
2011-06-22Labeling · Supplement 3LetterAP
2010-05-28Labeling · Supplement 1AP
2010-03-17OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →